Adenosine Myocardial Perfusion Imaging

Abstract

Adenosine myocardial perfusion imaging is a commonly used modality for the evaluation of patients with known or suspected coronary artery disease (CAD). In this review we discuss the pharmacology of adenosine and its effects on myocardial blood flow and the generation of perfusion defects during myocardial perfusion imaging (MPI), the indications and contraindications of MPI, stress protocols, side effects, hemodynamic and electrocardiographic changes, comparison to other stress MPI modalities, the role of adenosine MPI in special patient populations and the recent advances in the field with the emergence of the new selective adenosine agonists. Fig. (1). Effect of increasing intravenous adenosine doses on coronary flow reserve (CFR) compared to intracoronary papaverine. (From reference [111] with permission).

Optical Control of Adenosine A2A Receptor Using Istradefylline Photosensitivity

“…So far, three drugs targeting this receptor have received FDA approval. The endogenous ligand adenosine and the synthetic selective A 2A R agonist regadenoson are used in clinics as vasodilator agents, while the A 2A R antagonist istradefylline (also named KW-6002) has been approved as an adjunctive treatment for PD in combination with levodopa in Japan and USA. , Istradefylline is a styryl-xanthine analogue related to caffeine. It is a selective and potent competitive A 2A R antagonist .…”